以及：中度至重度银屑病患者甲氨蝶呤治疗毒性的预测生物标志物
, and : Predictive Biomarkers of Toxicity from Methotrexate Treatment in Patients Diagnosed with Moderate-to-Severe Psoriasis.
作者信息
Membrive-Jiménez Cristina, Vieira-Maroun Sayleth, Márquez-Pete Noelia, Cura Yasmin, Pérez-Ramírez Cristina, Tercedor-Sánchez Jesús, Jiménez-Morales Alberto, Ramírez-Tortosa María Del Carmen
机构信息
Pharmacogenetics Unit, Pharmacy Service, University Hospital Virgen de las Nieves, 18014 Granada, Spain.
Department of Biochemistry and Molecular Biology II, Faculty of Pharmacy, University of Granada, 18011 Granada, Spain.
出版信息
Biomedicines. 2023 Sep 19;11(9):2567. doi: 10.3390/biomedicines11092567.
BACKGROUND
Methotrexate (MTX) is one of the most extensively used drugs in the treatment of moderate-to-severe psoriasis (PS). However, it frequently must be suspended owing to the toxicity in certain patients.
OBJECTIVE
To evaluate the influence of , and in the development of MTX toxicity in PS.
METHODS
Retrospective cohort study with 101 patients. Five single-nucleotide polymorphisms (SNPs) were genotyped using real-time polymerase chain reaction with TaqMan probes.
RESULTS
Patients carrying rs2238476-AG genotype (AG vs. GG: OR = 8.04; 95% CI = 1.48-46.78; = 0.015); rs376154-GT and GG genotypes (GT vs. TT/GG: OR = 3.86; 95% CI = 1.17-13.92; = 0.031) and rs13120400-T allele (T vs. CC: OR = 8.33; 95% CI = 1.24-164.79; = 0.059) showed a higher risk of developing more than one adverse effect. The toxicity analysis by subtypes showed that the rs2238476-AG genotype (AG vs. GG: OR = 8.10; 95% CI = 1.69-46.63; = 0.011) and rs376154-GT genotype (OR = 4.11; 95% CI = 1.22-15.30; = 0.027) were associated with the appearance of asthenia. No association of the other ABCC1 polymorphisms (rs35592 and rs246240) with MTX toxicity was found.
CONCLUSION
, and polymorphisms can be considered to be risk biomarkers of toxicities in PS patients treated with MTX.
背景
甲氨蝶呤（MTX）是治疗中重度银屑病（PS）最广泛使用的药物之一。然而，由于某些患者的毒性，它经常必须停药。
目的
评估[具体内容缺失]在PS患者MTX毒性发生中的影响。
方法
对101例患者进行回顾性队列研究。使用TaqMan探针通过实时聚合酶链反应对5个单核苷酸多态性（SNP）进行基因分型。
结果
携带rs2238476 - AG基因型的患者（AG与GG：OR = 8.04；95%CI = 1.48 - 46.78；P = 0.015）；rs376154 - GT和GG基因型的患者（GT与TT/GG：OR = 3.86；95%CI = 1.17 - 13.92；P = 0.031）以及rs13120400 - T等位基因的患者（T与CC：OR = 8.33；95%CI = 1.24 - 164.79；P = 0.059）出现一种以上不良反应的风险更高。按亚型进行的毒性分析表明，rs2238476 - AG基因型（AG与GG：OR = 8.10；95%CI = 1.69 - 46.63；P = 0.011）和rs376154 - GT基因型（OR = 4.11；95%CI = 1.22 - 15.30；P = 0.027）与乏力的出现相关。未发现其他ABCC1多态性（rs35592和rs246240）与MTX毒性有关联。
结论
[具体内容缺失]多态性可被视为接受MTX治疗的PS患者毒性的风险生物标志物。
Zotero 插件